Abstract:The association of cdk4 with D-type cyclins to form functional kinase complexes is comparatively inefficient. This has led to the suggestion that assembly might be a regulated step. In this report we demonstrate that the CDK inhibitors p21(CIP), p27(KIP), and p57(KIP2) all promote the association of cdk4 with the D-type cyclins. This effect is specific and does not occur with other cdk inhibitors or cdk-binding proteins. Both in vivo and in vitro, the abundance of assembled cdk4/cyclin D complex increases directly with increasing inhibitor levels. The promotion of assembly is not attributable to a simple cell cycle block and requires the function of both the cdk and cyclin-binding domains. Kinetic studies demonstrate that p21 and p27 lead to a 35- and 80-fold increase in K(a), respectively, mostly because of a decrease in K(off). At low concentrations, p21 promotes the assembly of active kinase complexes, whereas at higher concentrations, it inhibits activity. Moreover, immunodepletion experiments demonstrate that most of the active cdk4-associated kinase activity also associates with p21. To confirm these results in a natural setting, we examine the assembly of endogenous complexes in mammary epithelial cells after release from a G(0) arrest. In agreement with our other data, cyclin D1 and p21 bind concomitantly to cdk4 during the in vivo assembly of cdk4/cyclin D1 complexes. This complex assembly occurs in parallel to an increase in cyclin D1-associated kinase activity. Immunodepletion experiments demonstrate that most of the cellular cyclin D1-associated kinase activity is also p21 associated. Finally, we find that all three CIP/KIP inhibitors target cdk4 and cyclin D1 to the nucleus. We suggest that in addition to their roles as inhibitors, the p21 family of proteins, originally identified as inhibitors, may also have roles as adaptor proteins that assemble and program kinase complexes for specific functions.

Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1

Inhibition of Cyclin-Dependent Kinases by P21.

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases

CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication

Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F

Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl

A Novel Cycline/cyclina-Cdk Inhibitor Targets P27(kip1) Degradation, Cell Cycle Progression and Cell Survival: Implications in Cancer Therapy.

New functional activities for the p21 family of CDK inhibitors.

P21 Disrupts the Interaction Between Cdk2 and the E2F-p130 Complex.

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

p27 inhibits CDK6/CCND1 complex formation resulting in cell cycle arrest and inhibition of cell proliferation

A cell cycle-regulated inhibitor of cyclin-dependent kinases.

p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21

Cell-cycle inhibitors: three families united by a common cause

Ubiquitylation and Proteasomal Degradation of the P21cip1, P27kip1and P57kip2cdk Inhibitors

Ubiquitylation and Proteasomal Degradation of the P21(Cip1), P27(Kip1) and P57(Kip2) Cdk Inhibitors

p21 in cancer: intricate networks and multiple activities

CDK Inhibitors: Cell Cycle Regulators and Beyond

The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy

Dynamic anticipation by Cdk2/Cyclin A-bound p27 mediates signal integration in cell cycle regulation

A P21(Waf1/Cip1) Carboxyl-Terminal Peptide Exhibited Cyclin-Dependent Kinase-Inhibitory Activity And Cytotoxicity When Introduced Into Human Cells